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Abstract
Background: Accurate methods of HIV incidence determination are critically needed to monitor the epidemic and determine
the population level impact of prevention trials. One such trial, Project Accept, a Phase III, community-randomized trial,
evaluated the impact of enhanced, community-based voluntary counseling and testing on population-level HIV incidence. The
primary endpoint of the trial was based on a single, cross-sectional, post-intervention HIV incidence assessment.
Methods and Findings: Test performance of HIV incidence determination was evaluated for 403 multi-assay algorithms
[MAAs] that included the BED capture immunoassay [BED-CEIA] alone, an avidity assay alone, and combinations of these
assays at different cutoff values with and without CD4 and viral load testing on samples from seven African cohorts (5,325
samples from 3,436 individuals with known duration of HIV infection [1 month to .10 years]). The mean window period
(average time individuals appear positive for a given algorithm) and performance in estimating an incidence estimate (in
terms of bias and variance) of these MAAs were evaluated in three simulated epidemic scenarios (stable, emerging and
waning). The power of different test methods to detect a 35% reduction in incidence in the matched communities of Project
Accept was also assessed. A MAA was identified that included BED-CEIA, the avidity assay, CD4 cell count, and viral load that
had a window period of 259 days, accurately estimated HIV incidence in all three epidemic settings and provided sufficient
power to detect an intervention effect in Project Accept.
Conclusions: In a Southern African setting, HIV incidence estimates and intervention effects can be accurately estimated
from cross-sectional surveys using a MAA. The improved accuracy in cross-sectional incidence testing that a MAA provides is
a powerful tool for HIV surveillance and program evaluation.
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Introduction
Accurate methods for estimating HIV incidence are needed to
monitor the epidemic and evaluate interventions for HIV
prevention [1]. In clinical trials, HIV incidence is usually assessed
by enrolling HIV-uninfected individuals and following them over
time to detect HIV acquisition. An alternate approach is to assess
HIV incidence by analyzing specimens from cross-sectional
surveys without longitudinal follow-up [2]. This approach may
be needed for evaluation of population-level interventions for HIV
prevention, particularly when HIV testing is part of a combination
prevention strategy [3,4]. In this report, we describe the
development of methods that were used to analyze HIV incidence
in a large, Phase III community randomized trial: National
Institute of Mental Health (NIMH) Project Accept (HIV
Prevention Trials Network 043 [HPTN 043]) [5]. Project Accept
is one of the largest randomized, controlled trial performed to
date, and is the first randomized controlled trial with a primary
study endpoint based solely on cross-sectional estimation of HIV
incidence.
Project Accept evaluated the impact of integrated behavioral
interventions on HIV incidence in 48 paired communities (34 in
Africa, 14 in Thailand) [16]. Control communities received
standard, clinic-based, voluntary counseling and testing services;
intervention communities received enhanced, community-based
voluntary counseling and testing services. After a 3-year interven-
tion period, samples were collected from individuals in the
communities (aged 18 to 32 years) in a single cross-sectional
survey. When the trial was designed, the study plan was to estimate
HIV incidence using the BED capture immunoassay (BED-CEIA,
Calypte Biomedical Corporation, Lake Oswego, OR, USA) [6].
That approach was not used because the BED-CEIA was later
found to overestimate incidence in many settings [7].
In this report, we describe the laboratory and statistical analysis
that was used to identify an alternate testing strategy for HIV
incidence estimation in Project Accept. The testing strategies that
were evaluated used multiple biomarkers to assess HIV incidence
[8]. This approach was based on recent success using a multi-assay
algorithm (MAA) to estimate HIV incidence in populations in the
United States (clade B settings) [9–11]. That MAA combines
serologic assays (the BED-CEIA and an antibody avidity assay)
with non-serologic biomarkers (CD4 cell count and HIV viral
load) to identify individuals who were likely to have been recently
infected at the time of sample collection (referred to in this report
as MAA positive). In Project Accept, because HIV prevalence in
the communities in Thailand was low (,1%, [12]), data from
Thailand were not included in the primary endpoint analysis.
Therefore, we focused on identifying a MAA that could be used to
estimate incidence in the African communities of the trial, using
validation samples obtained from seven African cohorts.
Development of methods for cross-sectional HIV incidence
estimation is challenging for several reasons. First, an assay or
MAA must have a suitable mean window period; this term refers
to the average period of time that individuals are identified as
positive by a specific assay or MAA. If the window period is too
short, fewer individuals will be classified as positive, resulting in
higher variance and lower precision of incidence estimates,
reducing the power to determine an intervention effect. Con-
versely, if the window period is too long, the precision of incidence
estimates will be reduced because of high bias; furthermore, if too
many individuals with long-term infection (e.g, infected .1 year)
test positive by an assay or MAA, the incidence estimates will not
reflect the current epidemic. Bias is reduced when the probability
of being classified as positive approaches zero as the time since
infection increases [13,14]. The performance of serologic assays
used for cross-sectional incidence estimation may also be affected
by HIV viral load, frequency and duration of antiretroviral
treatment (ART), the stage of HIV disease, HIV subtype, and race
[15–21]. Finally, the performance of assays and MAAs for
incidence estimation varies by the stage of the epidemic. For
example, a given test method may perform well in an emerging
epidemic with high incidence, but may not perform well in waning
epidemic where incidence is low and many individuals have
advanced HIV disease. In this report, we describe the laboratory
and statistical methods used to identify a MAA for incidence
analysis in Project Accept.
Methods
Samples used for analysis
Samples obtained from seven African cohort studies and clinical
trials (Table 1) were used for validation. Samples were selected
based on availability of stored plasma, known infecting subtype,
known duration of infection (known date of a prior positive and/or
negative HIV test), and available CD4 cell count data from the
time of sample collection. Of the samples that did not have a
known prior HIV negative time point, 99.3% were from
individuals who were HIV seropositive for .1 year and 52.7%
were known to be from individuals who were HIV seropositive for
.2 years. Infection times were either interval-censored (the dates
of the first positive and the last negative HIV tests were available)
or right-censored (the date of the last negative test was unknown).
In the latter case, we assigned the 14th birthday as the date of the
last negative test and treated the infection time as interval-
censored. Interval-censored infection times were randomly
imputed in the simulations. For almost all of the samples, the
infection time was generated from the uniform distribution
between the last negative and first positive test dates. However,
for 147 samples from subjects who had another visit following the
current sample date, the infection time was generated from a
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posterior Weibull density truncated to the interval between the last
negative and first positive test dates. We assumed a Weibull
distribution on the survival of HIV-infected subjects and a uniform
prior distribution of the infection time, and calculated the posterior
distribution of the infection time given the date of the last known
visit. We used the Weibull survival distribution with the shape
parameter 1.856 and rate parameter 4358.5 days. The truncated
Weibull density puts more weight on the more recent infection
times if the subject is known to have survived for a long time after
the first positive test date and so improves the precision of the
imputed infection times compared to the uniform distribution.
More details on these methods are presented elsewhere [22].
Samples from Botswana, Malawi, South Africa, and Zimbabwe
were assumed to come from individuals infected with HIV subtype
C [23]. The HIV subtypes of samples from Uganda and Kenya
were determined previously [24–28].
Serologic testing
Samples were tested by the BED-CEIA; [6] samples were run in
duplicate and the average normalized optical density (OD-n) value
was used for analysis. Antibody avidity was measured using a
modified version of the Genetic Systems 1/2+O ELISA (BioRad,
Hercules, CA) [29]. For this assay, duplicate sample aliquots were
diluted 1:10 and incubated at 4uC for 30 minutes (initial antibody-
binding step). Samples were then incubated for 30 minutes at
37uC with or without the chaotropic agent, diethylamine (antibody
disassociation step). The avidity index (AI) was calculated as
follows: AI = [optical density of the diethylamine-treated well]/
[optical density of the non-treated well] 6100.
HIV viral load testing
If a viral load result was not available, viral load testing was
performed using the Amplicor HIV-1 Monitor test version 1.5
(Roche Diagnostics, Indianapolis, IN). Viral load testing was only
performed for samples that had a BED-CEIA result ,1.5 OD-n,
an AI ,90%, and a CD4 cell count .150 cells/mm3.
Statistical methods
To compare the performance of various testing algorithms, we
constructed 403 MAAs that included one or more of the following
assays: BED-CEIA, the avidity assay, CD4 cell count, and HIV
viral load. The ranges of cutoffs used for each assay were as
follows: BED-CEIA: 0.5 to 1.5 OD-n (steps of 0.1 OD-n); the
avidity assay: 30% to 90% (steps of 10% AI); CD4 cell count: 150,
200, and 250 cells/mm3; all MAAs that included HIV viral load
used a cutoff of .400 copies/mL. The MAAs included the BED-
CEIA alone, the avidity assay alone, or these two assays in
combination with or without inclusion of CD4 cell count; HIV
viral load was only included for MAAs that included a CD4 cell
count with a cutoff .200 cells/mm3.
The mean window period for each MAA was calculated by
integrating estimated sensitivity of the MAA, as described [9], with
the following caveat: the maximum duration of HIV infection was
assumed to be 12 years [22]. The performance of the MAAs for
estimating HIV incidence was evaluated in simulated populations
with 10% prevalence using three epidemic scenarios (emerging,
stable, and waning epidemics). Detailed descriptions of the
statistical methods and simulation exercises are described
elsewhere [22], The three scenarios were simulated using data
from the sample set described in Table 1. For each scenario, data
from 200 individuals with different durations of HIV infection
were repeatedly sampled. The bias, variance, and root mean
square error (RMSE) of the incidence estimate for each of the 403
MAAs was determined for each of the three scenarios. The RMSE
measures the overall precision of estimated incidence by combin-
ing the bias and variance. The same performance measures were
used to evaluate incidence estimates calculated from simulated 6-
month and one-year follow-up assessments. In the final evaluation,
the data were used to simulate the capacity of selected MAAs to
accurately estimate a difference in HIV incidence in the control
and intervention communities of Project Accept [22], Finally, the
power to detect a 35% decrease in incidence and coverage of
confidence intervals for the intervention effect were determined for
a stable epidemic setting. The results were compared to simulated
intervention effect estimates obtained by 6-month follow-up.
Human subjects protection
Written informed consent was obtained from study participants
and all studies were reviewed and approved by relevant
institutional review boards. The study for cross sectional incidence
testing on stored study samples was approved by the institutional
review board of the Johns Hopkins University. The primary
studies for the collection of the samples evaluated were approved
by the University of KwaZulu-Natal Biomedical Research Ethics
Committee, Medical Research Council of Zimbabwe, Family
Health International Protection of Human Subjects Committee,
Table 1. Samples used for analysis.
Gender Subtype A Subtype C Subtype D All subtypes
Cohort a (% female) # subjects # samples # subjects # samples # subjects # samples # subjects # samples
CAPRISA 100 0 0 97 552 0 0 97 552
FHI/Uganda 100 46 225 1 3 23 197 70 425
FHI/Zimbabwe 100 0 0 132 339 0 0 132 339
HPTN 039 100 0 0 45 135 0 0 45 135
Partners 64.3 63 155 563 625 18 37 644 817
PEPI 100 0 0 1,663 1,664 0 0 1,663 1,664
Rakai 62.9 254 431 18 37 513 925 785 1,393
Total 84.8 363 811 2,519 3,355 554 1,159 3,436 5,325
aSamples were obtained from the following clinical cohorts (see Methods): CAPRISA: the CAPRISA 004 Study/TRAPS [32]; FHI/Uganda and FHI/Zimbabwe: the FHI360
Hormonal Contraception and HIV (HC-HIV) Trial [24]; HPTN 039: the HIV Prevention Trials Network 039 Trial [33]; Partners: the Partners in Prevention HSV/HIV
Transmission Study [34]; PEPI: the Pre-Exposure Prophylaxis in Infants – Malawi Trial [35]; Rakai: the Rakai Health Sciences Program [36].
doi:10.1371/journal.pone.0078818.t001
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the South African Medicines Control Council, the institutional
review board at the University of Malawi, Ethics Committee of the
Uganda Virus Research Institute and the Committee for Human
Research at Johns Hopkins University and the University of
Washington Human Subjects Review Committee.
Results
Performance of the BED-CEIA and avidity assay in
subtypes A, C, and D
Because HIV subtype can affect performance of the BED-CEIA
and avidity assays [18,30], we first considered the potential impact
of HIV subtype on incidence estimation in Project Accept which
was conducted in South Africa, Zimbabwe, and Tanzania. Most
HIV infections in South Africa and Zimbabwe are subtype C,
while Tanzania has three prevalent subtypes: A, C, and D [23]. To
evaluate incidence algorithms for use in Project Accept, we
obtained validation samples from seven African studies conducted
in countries where subtypes A, C, and D are prevalent (Table 1).
This sample set included 5,325 samples from 3,436 individuals
with known duration of HIV infection (from 1 month to
.10 years, see Methods).
First, we evaluated the performance of the BED-CEIA and
avidity assay as a function of duration of infection for subtypes A,
C, and D (Figure 1). The mean window period for each assay and
each subtype were obtained using the standard assay cutoffs
(Table 2). For all three subtypes, the mean window period was
longer for the BED-CEIA alone than for the avidity assay alone.
For both assays, the mean window periods varied considerably
among subtypes and were longest for subtype D (.2.5 years for
the BED-CEIA, .1.5 years for the avidity assay). We also
compared the proportion of individuals infected .2 years who
had BED-CEIA results ,0.8 OD-n or avidity assay results ,40%
AI (Table 2). Previous reports indicated that the frequency of
subtype D in Tanzania was low [12,23]; this was confirmed by
subtyping a subset of the samples from Project Accept [31].
Because subtype D infections were not likely to have a significant
impact on HIV incidence estimates in Project Accept, subsequent
analyses did not include subtype D validation samples. After
removing the subtype D samples, the validation sample set
included 4,166 samples from 2,882 individuals (median age:
27.8 years, interquartile range [IQR]: 24.1 to 32.5 years; 88%
women). The performance of the BED-CEIA and the avidity assay
was similar for subtypes A and C (Figure 1, Table 2).
Performance of MAAs for identifying individuals with
recent HIV infection
We evaluated the performance of 403 MAAs (see Methods).
The mean window period for each MAA is presented in Table S1.
Below, we present more detailed information for four of the testing
algorithms: the BED-CEIA alone (using the standard assay cutoff
Figure 1. BED-CEIA and avidity assay results for HIV subtypes A, C, and D. Samples from the validation sample set were analyzed using the
BED-CEIA (Panels A–C) and the avidity assay (Panels D–F). Results are shown for each assay for subtypes A, C, and D as a function of duration of HIV
infection (years after HIV seroconversion). Data are shown for 50 randomly-selected samples for each 6-month interval after seroconversion. The HIV
incidence testing algorithms evaluated in this report only included algorithms with BED-CEIA results #1.5 OD-n or avidity results #90% AI (dashed
lines).
doi:10.1371/journal.pone.0078818.g001
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of 0.8 OD-n), the avidity assay alone (using the standard assay
cutoff of 40% AI)], and two MAAs that include the BED-CEIA,
the avidity assay, CD4 cell count and viral load. One of these two
MAAs was shown to accurately estimate HIV incidence in subtype
B settings (BED-CEIA ,1.0 OD-n + AI ,80% + CD4 cell count
.200 cells/mm3 + viral load .400 copies/mL) when testing the
samples at the end of follow-up in three clinical studies and
comparing the cross-sectional incidence estimates to the incidence
observed during study follow-up [9–11]. Based on its performance
described below, the other MAA was ultimately selected for
endpoint analysis in Project Accept (BED-CEIA ,1.2 OD-n + AI
,90% + CD4 cell count .200 cells/mm3 + viral load .400
copies/mL) [22].
The proportion of samples positive for each of the four testing
algorithms was determined as a function of duration of infection
(Figure 2). Consistent with results shown in Figure 1, a high
proportion of individuals infected .2 years were positive by the
BED-CEIA alone (7.9%). The other three testing approaches
identified a lower proportion of these long-term infections as
positive (1.9% for the avidity assay, 0.8% and 1.5% for the 4-assay
MAAs). For individuals infected ,6 months, 68.5% were positive
using the avidity assay alone, 75.6% were positive using the MAA
that was previously optimized for incidence estimation in clade B
epidemics, and 81.5% were positive using the MAA that was
ultimately selected for analysis of the Project Accept endpoint. The
MAA that was ultimately selected for use in Project Accept
identified 27.5% of those infected 0.5–1 year and 8.8% of those
infected 1–2 years as positive.
Performance of MAAs for estimating HIV incidence in
different epidemic scenarios
The overall performance of incidence assays and MAAs is
affected by the distribution of infection times in a population.
Because the stage of the HIV epidemic in the Project Accept
communities was not known, we evaluated the performance of the
403 MAAs for estimating HIV incidence in three simulated
epidemic scenarios: emerging, stable, and waning epidemics.
These scenarios were constructed by randomly selecting samples
from the validation data set so that the distribution of durations of
infection corresponded to the desired scenario (see Methods,
Figure 3). In the stable epidemic, 5.5% of individuals were infected
,0.5 years, 13.3% were infected 0.5–2 years, 29.0% were
infected 2–5 years, 33.4% were infected 5–10 years, and 17.8%
were infected .10 years. For the emerging epidemic, these
percentages were 17.7%, 42.9%, 38.4%, and 1.0%, respectively;
for the waning epidemic, these percentages were 0.7%, 1.6%,
44.0%, and 53.7%, respectively.
The bias, variance, and RMSE were calculated for each MAA
in the three epidemic scenarios. Results obtained using the BED-
CEIA alone, the avidity assay alone, the best performing 2-assay
MAA (BED-CEIA ,0.8 OD-n + AI ,70%) and the two 4-assay
MAAs described above are shown in Table 3; results for all 403
MAAs are shown in Supplemental Table 1. The bias reflects the
difference between the estimated incidence and the true incidence.
Among the 403 MAAs, the bias ranged from 26.1% to 263.3%
in the emerging epidemic scenario, from 29.2% to 226.6% in the
stable epidemic scenario, and from 40.6% to 346.7% in the
waning epidemic scenario. In the stable and emerging epidemic
scenarios, the bias was lower for MAAs that used serologic assays
in combination with CD4 cell count and viral load (Table S1).
The RMSE ranged from 0.20 to 1.01 in the emerging epidemic
scenario, from 0.28 to 0.55 in the stable epidemic scenario, and
from 0.65 to 1.50 in the waning epidemic scenario. The best
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algorithms tested. Though this MAA was comparable to the best
3- and 4-assay MAAs in the waning epidemic scenario, it
performed poorly in stable and emerging scenarios, In the
emerging and waning epidemic scenarios, the lowest precision
values (highest RMSEs) were obtained using the BED-CEIA alone
or the avidity assay alone.
Finally, we compared the capacity of the four testing algorithms
to accurately detect a 35% difference in HIV incidence in the
control and intervention communities of Project Accept (Table 4)
[22]. The intervention effect was accurately estimated by both of
the 4-assay MAAs, but was underestimated using BED-CEIA
alone or the avidity assay alone. The percentage of 95%
confidence intervals that covered the true intervention effect was
.93% for both 4-assay MAAs, but was unacceptably low for the
BED-CEIA alone or the avidity assay alone. The MAA that was
ultimately selected for primary endpoint analysis in Project Accept
(BED-CEIA ,1.2 OD-n + avidity index ,90% + CD4 cell count
.200 cells/mm3 + viral load .400 copies/mL) provided the
largest power for detecting a 35% reduction in HIV incidence and
had minimal bias in estimating incidence across differing epidemic
scenarios. This MAA had better precision, power, and negligible
bias compared to a simulated 6-month follow-up study using the
same validation sample set. In a separate simulation, we showed
that both of the 4-assay MAAs maintained the required probability
of type I error, provided that the scenarios in the paired
communities were the same.
Figure 2. Proportion of samples classified as positive using the BED-CEIA alone, the avidity assay alone, and two MAAs. Subtype A
and C samples were analyzed using the BED-CEIA alone (using the standard assay cutoff of 0.8 OD-n, black bars), the avidity assay alone (using the
standard assay cutoff of 40% AI, dark grey bars), and two MAAs that included multiple biomarkers, (BED-CEIA ,1.0 OD-n + AI ,80% + CD4 cell count
.200 cells/mm3 + viral load .400 copies/mL, medium grey bars; BED-CEIA ,1.2 OD-n + AI ,90% + CD4 cell count .200 cells/mm3 + viral load .400
copies/mL, light grey bars). For each test method, the percentage of samples classified as positive was determined as a function of the duration of
HIV infection (years after HIV seroconversion). N indicates the number of samples analyzed for each time period (e.g., 0–0.5 years after
seroconversion).
doi:10.1371/journal.pone.0078818.g002
Figure 3. Simulated epidemic scenarios. HIV incidence testing algorithms were assessed using three simulated epidemic scenarios: an emerging
epidemic (black bars), a stable epidemic (dark grey bars), and a waning epidemic (light grey bars). The plot shows the percentage of HIV-positive
samples included in each scenario for different time periods (years after HIV seroconversion).
doi:10.1371/journal.pone.0078818.g003
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Discussion
We evaluated the performance of incidence assays and MAAs
using data from a large set of validation samples from Africa.
These samples were from individuals with a broad range of
infection times who had CD4 cell count data available from the
time of sample collection. We found that testing algorithms that
included multiple assays were superior to single serologic assays;
the incidence estimates obtained using multiple assays had lower
bias and better precision. We used simulation exercises to
demonstrate that the 4-assay MAA that was selected for use in
Project Accept provided a more precise estimate of the ratio
between incidence in the intervention and control communities
than would have been obtained by following a cohort for
seroconversion over a 6-month period.
Our findings demonstrate the importance of including samples
from very long-term infections when validating methods for
cross-sectional HIV incidence estimation. Using a sample set that
included individuals infected .10 years, the mean window period
for the BED-CEIA was 1.63 years, which is approximately three
times longer than the mean window period previously reported for
this assay [18]. We found that the BED-CEIA and avidity assay
frequently identified individuals infected .2 years as positive. This
effect was most pronounced for subtype D. Previous studies have
shown that misclassification of subtype D samples using these
assays reflects differences in the serologic response to subtype D
infection compared to subtype A infection; differences in the
sequences of subtype D viruses in the region corresponding to the
BED-CEIA target antigen also negatively affect assay performance
[30]. We recommend against using the BED-CEIA or Bio-Rad
avidity assays for cross-sectional incidence estimation in popula-
tions that include a substantial proportion of subtype D-infected
individuals. Additional studies should be performed using different
test methods [e.g., different assay (s) and/or different cutoff (s)] to
Table 3. Accuracy of incidence estimates obtained using the BED-CEIA alone, the avidity assay alone, a two-assay multi assay
algorithm (MAA), and two four-assay MAAs in three epidemic scenarios*.
Epidemic scenario
Stable epidemic Emerging epidemic Waning epidemic
Window Period (annual incidence 1.29%) (annual incidence 4.18%) (annual incidence 0.16%)
Algorithm (years) Rank Rel. bias RMSE Rank Rel. bias RMSE Rank Rel. bias RMSE
6-month follow-up – – 27.9% 0.32 – 25.7% 0.17 – 18.6% 0.51
BED ,0.8 1.63 95 223.2% 0.32 396 249.9% 0.70 396 221.4% 1.19
AI ,40 0.67 339 224.5% 0.42 390 237.0% 0.49 390 149.7% 1.06
BED ,0.8, AI ,70 0.67 257 220.2% 0.38 309 225.4% 0.33 29 50.0% 0.71
BED ,1.0, AI ,80,
CD4.200, VL.400
0.56 125 29.9% 0.33 7 213.1% 0.21 20 49.0% 0.71
BED ,1.2, AI ,90,
CD4.200, VL.400
0.71 23 211.4% 0.29 91 217.6% 0.24 78 64.2% 0.75
*MAA: multi-assay algorithm; BED-CEIA: BED capture immunoassay (results expressed as normalized optical density units); AI: avidity index (results expressed as a
percentage); CD4: CD4 cell count (results expressed as cells/mm3); VL: viral load (results expressed as HIV RNA copies/mL); yrs: years; Rel. bias: relative bias; RMSE: root
mean square error. The lower two rows show results for MAAs (see text); for these MAAs, individuals are classified as MAA positive if they have results for all for assays
that are below/above the cutoffs indicated.
The relative bias (in % of true incidence over 12 months) and precision of incidence estimates (expressed as the root mean square error for log incidence, RMSE) are
shown for a 6-month cohort follow-up estimator and four cross-sectional testing algorithms in three different epidemic scenarios. The ranks show the relative ranking of
each algorithm among the 403 evaluated algorithms according to precision of incidence estimation (RMSE).
doi:10.1371/journal.pone.0078818.t003
Table 4. Capacity to estimate and detect a 35% reduction in HIV incidence in the Southern African communities of Project Accept





Std. error of log
estimated RR Power
Coverage of 95% confidence
intervals for RR
6-month follow-up 0.631 0.182 70.4% 94.7
BED ,0.8 0.763 0.109 68.4% 57.3
AI ,40 0.705 0.165 56.5% 88.8
BED ,1.0, AI ,80, CD4 .200, VL .400 0.653 0.169 69.7% 95.6
BED ,1.2, AI ,90, CD4 .200, VL .400 0.663 0.157 75.5% 93.1
*BED-CEIA: BED capture immunoassay (results expressed as normalized optical density units); AI: avidity assay (results expressed as a percentage, avidity index); CD4:
CD4 cell count (results expressed as cells/mm3); VL: viral load (results expressed as HIV RNA copies/mL); Std: standard; RR: relative risk.
The table shows the mean estimated intervention effect, empirical standard error of log estimated intervention effect, the power to detect the 35% difference in
incidence, and the coverage of the 95% confidence intervals obtained by a simulation study under the stable epidemic scenario. The lower two rows show results for
MAAs (see text); for these MAAs, individuals are classified as MAA positive if they have results for all for assays that are below/above the cutoffs indicated.
doi:10.1371/journal.pone.0078818.t004
Evaluation of HIV Incidence in Southern Africa
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e78818
identify an effective method for cross-sectional incidence estima-
tion in subtype D endemic areas. Fortunately, the prevalence of
subtype D was low in the Tanzanian communities in Project
Accept [31]. Therefore, we felt it was reasonable to use a MAA
that was optimized for subtypes A and C for estimating incidence
in the four African sites in Project Accept.
In this report, we used a novel approach to compare the
performance of a large set of MAAs that employed different
combinations of assays and assay cutoffs in three different
simulated epidemic scenarios. The MAAs that included both
serologic assays and non-serologic biomarkers (CD4 count and
viral load) had lower bias and variance for estimating incidence
than algorithms based on a single assay. The MAA that provided
the greatest power to detect a reduction in incidence in Project
Accept used relatively high cutoffs for both the BED-CEIA (,1.2
OD-n) and the avidity assay (,90% AI), which increased the
identification of individuals infected within 1 year. Use of these
higher cutoffs for increased the frequency of misclassification,
though it was still ,1.5% for individuals infected .2 years.
HIV viral load was included in 77 of the 403 MAAs evaluated
in this study. This biomarker identifies both elite suppressors and
individuals who are virally suppressed from ART. It is important
to identify both of these groups, since viral suppression is
associated with down-regulation of the humoral immune response
to HIV infection and with increased rates of false-recent
misclassification using serologic HIV incidence assays [2]. ART
also serves as an independent surrogate for non-recent HIV
infection, since individuals with recent HIV infection are not likely
to be identified or to access ART in many settings. We recognize
that the 4-assay MAA selected for endpoint analysis in Project
Accept may misclassify some individuals on ART who are not
virally suppressed (e.g., those with low viral loads that are .400
copies/ml). This was addressed in Project Accept using a two-step
approach: first, the MAA was used to identify samples from
individuals who were likely to have had recent infection; second,
these samples were tested for the presence of antiretroviral drugs
[31]. When using antiretroviral drug testing in an HIV incidence
assessment, it is important to consider the test results in the context
of antiretroviral drug regimens that were used in the communities
at the time the incidence survey was conducted; this should take
into account use of antiretroviral drugs for HIV prevention (e.g.,
for prevention of mother-to-child transmission, where those
receiving prophylaxis may have been recently infected).
The novel approach that was used to select an optimal testing
algorithm for HIV incidence assessment in Project Accept is of
general relevance to HIV prevention trials. We demonstrate that a
large validation data set from individuals with known duration of
infection can be used to assess the performance of various testing
algorithms in terms of estimating incidence, providing estimates of
bias and precision, and comparing the cross-sectional estimates to
cohort-based estimates. We also used an empirical approach to
determine assay cutoffs that optimized the precision of cross-
sectional incidence estimates using MAAs. The methods described
in this report could be used for cross-sectional incidence
assessment in non-subtype D epidemics of Southern Africa for
HIV prevention studies, surveillance, and other purposes.
Supporting Information
Table S1 Window periods, bias, root square mean error
(RMSE) for stable, emerging and waning epidemics for 403
multi-assay algorithms (MAAs). *
*BED: BED capture immunoassay (results expressed as normal-
ized optical density units); AI: avidity assay (results expressed as a
percentage, avidity index); CD4: CD4 cell count (results expressed
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